Biotech News

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine Inc. (LPCN)Lipocine Inc.2026-01-20 13:00 ESTClinical readout

LPCN (LPCN) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is lpcn.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Lipocine Inc.

Oral Drug-Delivery Platform Lipocine develops oral formulations intended to improve the delivery of therapeutics that are otherwise difficult to administer effectively by mouth. LPCN 1154 LPCN 1154 is an oral formulation of brexanolone developed for postpartum depression. A Phase 3 study did not meet its primary endpoint, leaving the...

Recent company news

LPCNLipocine Inc.2026-08-04 12:00 EST

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

LPCNLipocine Inc.2026-08-03 12:00 EST

Lipocine Appoints Michael J. Grissinger to Board of Directors

LPCNLipocine Inc.2026-06-04 12:00 EST

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

LPCNLipocine Inc.2026-05-19 12:00 EST

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

LPCNLipocine Inc.2026-05-18 12:00 EST

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Stock data

Close: 2.13 USD
Market cap: 18.55M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States